They combined anti-PD-1 immunotherapy with CXCR4-targeting p53 mRNA nanoparticles, which revealed the massive potential of this combination strategy in enhancing the liver cancer anti-tumor immune response and suppressing tumor growth (209). Here, CXCR4 is linked to neoplasm.